The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD
Open accessAbstract
BACKGROUND: As chronic obstructive pulmonary disease (COPD) is a heterogeneous disease it is unlikely that all patients will benefit equally from a given therapy. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, has been shown to improve lung function in moderate and severe COPD but its effect on exacerbations in unselected populations was inconclusive. This led to the question of whether a responsive subset existed that could be investigated further. METHODS: The datasets of two previous replicate, randomized, double-blind, placebo-controlled, parallel-group studies (oral roflumilast 500 μg or placebo once daily for 52 weeks) that were inconclusive regarding exacerbations were combined in a post-hoc, pooled analysis to determine whether roflumilast reduced exacerbations in a more precisely defined patient subset. RESULTS: The pooled analysis included 2686 randomized patients. Roflumilast significantly decreased exacerbations by 14.3% compared with placebo (p = 0.026). Features associated with this reduction were: presence of chronic bronchitis with or without emphysema (26.2% decrease, p = 0.001), presence of cough (20.9% decrease, p = 0.006), presence of sputum (17.8% decrease, p = 0.03), and concurrent use of inhaled corticosteroids (ICS; 18.8% decrease, p = 0.014). The incidence of adverse events was similar with roflumilast and placebo (81.5% vs 80.1%), but more patients in the roflumilast group had events assessed as likely or definitely related to the study drug (21.5% vs 8.3%). CONCLUSIONS: This post-hoc, pooled analysis showed that roflumilast reduced exacerbation frequency in a subset of COPD patients whose characteristics included chronic bronchitis with/without concurrent ICS. These observations aided the design of subsequent phase 3 studies that prospectively confirmed the reduction in exacerbations with roflumilast treatment. TRIALS REGISTRATION: ClinicalTrials.gov identifiers: NCT00076089 and NCT00430729.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
Hurst, J. R., Vestbo, J., Anzueto, A., Locantore, N., Müllerova, H., Tal-Singer, R., Miller, B., Lomas, D. A., Agusti, A., MacNee, W., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909883 · Cited by 2,981
Self-citationEffect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease
SEEMUNGAL, T. A. R., DONALDSON, G. C., PAUL, E. A., BESTALL, J. C., JEFFRIES, D. J., & WEDZICHA, J. A. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.5.9709032 · Cited by 2,312
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
Soler-Cataluna, J. J. (2005) · Thorax · doi:10.1136/thx.2005.040527 · Cited by 1,931
Global burden of COPD: systematic review and meta-analysis
Halbert, R. J., Natoli, J. L., Gano, A., Badamgarav, E., Buist, A. S., & Mannino, D. M. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00124605 · Cited by 1,499
COPD exacerbations: Defining their cause and prevention
Wedzicha, J. A., & Seemungal, T. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61382-8 · Cited by 1,370
Genetic epidemiology of copd (copdgene) study design
Regan, E. A., Hokanson, J. E., Murphy, J. R., Make, B., Lynch, D. A., Beaty, T. H., Curran-Everett, D., Silverman, E. K., & Crapo, J. D. (2011) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412550903499522 · Cited by 1,313
Calverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A., Anderson, J., & Maden, C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12459-2 · Cited by 1,221
Self-citationChronic Obstructive Pulmonary Disease Phenotypes: The Future of COPD
Han, M. K., Agusti, A., Calverley, P. M., Celli, B. R., Criner, G., Curtis, J. L., Fabbri, L. M., Goldin, J. G., Jones, P. W., MacNee, W., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200912-1843cc · Cited by 1,032
Self-citationBurden and clinical features of chronic obstructive pulmonary disease (COPD)
Pauwels, R. A., & Rabe, K. F. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16855-4 · Cited by 1,004
Cited by
Inflammatory mechanisms in patients with chronic obstructive pulmonary disease
Barnes, P. J. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.05.011 · Cited by 1,683
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
Wedzicha, J. A., Miravitlles, M., Hurst, J. R., Calverley, P. M. A., Albert, R. K., Anzueto, A., Criner, G. J., Papi, A., Rabe, K. F., Rigau, D., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00791-2016 · Cited by 683
Self-citationCellular and Molecular Mechanisms of Chronic Obstructive Pulmonary Disease
Barnes, P. J. (2014) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2013.10.004 · Cited by 488
COPD Guidelines: A Review of the 2018 GOLD Report
Mirza, S., Clay, R. D., Koslow, M. A., & Scanlon, P. D. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.05.026 · Cited by 444
Martinez, F. J., Calverley, P. M. A., Goehring, U.-M., Brose, M., Fabbri, L. M., & Rabe, K. F. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62410-7 · Cited by 374
Self-citation
Metadata
- Authors
- Rennard, S. I., Calverley, P. M., Goehring, U. M., Bredenbröker, D., & Martinez, F. J.
- Venue
- Respiratory Research
- Published
- 2011-12
- Volume
- 12
- Issue
- 1
- Pages
- 18-18
- ISSN
- 1465-9921 (ISSN-L)
- 1465-993X
- OpenAlex
- W2127294121
- Cited by
- 284
- References
- 31
- FWCI
- 28.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. https://app.cochat.ai/papers/10.1186/1465-9921-12-18
- The paper
- Rennard, S. I., Calverley, P. M., Goehring, U. M., Bredenbröker, D., & Martinez, F. J. (2011). Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respiratory Research. https://doi.org/10.1186/1465-9921-12-18
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.